Literature DB >> 3276396

Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer.

H W Müller-Gärtner1, C Schneider.   

Abstract

This study delineates tumor characteristics which predispose serum thyroglobulin (TG) to be undetectable in patients in spite of persistent or recurrent differentiated thyroid cancer. Three hundred seventy four thyroid carcinoma patients with completed thyroid ablation were investigated by means of conventional diagnostic procedures (131 iodine total-body scan, x-ray, TG determination) and, in addition, with high-resolution sonographic study of the neck. Sensitivity of TG for the detection of metastases amounted to 83% under TSH stimulation and 50% under thyroxine (T4) treatment. Specificity proved to be 95% under TSH stimulation and 99% under T4 treatment. Common features of the tumors associated with false-negative TG determinations (n = 16) were papillary histologic characteristics, manifestation in lymph nodes of the neck or mediastinum, and small size. It is therefore necessary for the early detection of persistent or recurrent papillary cancer metastases to perform in addition to 131 iodine scans high-resolution sonography of the neck in combination with the determination of TG serum concentrations under endogenous TSH stimulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276396     DOI: 10.1002/1097-0142(19880301)61:5<976::aid-cncr2820610520>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.

Authors:  D Rubello; M E Girelli; D Casara; M Piccolo; A Perin; B Busnardo
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

2.  Retrospective Analysis of Thyroid Cancer Patients.

Authors:  S S Anand; V Sood; P G Kumar; I Sinha; A Kotwal
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Value of post-therapeutic ¹³¹I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma.

Authors:  Chen-Tian Shen; Wei-Jun Wei; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Endocrine       Date:  2015-06-21       Impact factor: 3.633

4.  Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.

Authors:  Dong-Jun Lim; Joo Hyun O; Min-Hee Kim; Ji-Hyun Kim; Hyuk-Sang Kwon; Sung-Hoon Kim; Moo-Il Kang; Bong-Yun Cha; Kwang-Woo Lee; Ho-Young Son
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

5.  Micrometastasis of papillary thyroid carcinoma in a human immunodeficiency virus-infected patient: a case report and discussion.

Authors:  Célia Lloret Linares; Didier Troisvallets; Pierre Sellier; André Aurengo; Laurence Leenhardt
Journal:  Med Oncol       Date:  2009-08-06       Impact factor: 3.064

6.  Predictive value of serum thyroglobulin in treated patients with differentiated thyroid carcinoma.

Authors:  D C Stephen; M S Seshadri; R Oommen; A Nair; S Swaminathan; A S Kanagasabapathy
Journal:  Indian J Clin Biochem       Date:  1999-01

7.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

Review 8.  Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

9.  A rare case report of very low thyroglobulin and a negative whole-body scan in a patient with a solid variant of papillary thyroid carcinoma with distant metastases.

Authors:  Wei Li; Danyang Sun; Hui Ming; Guizhi Zhang; Jian Tan
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

10.  Is Every Patient Followed up as a Papillary Thyroid Cancer Patient Really That?

Authors:  Ummuhan Abdulrezzak; Ahmet Tutus; Mustafa Kula; Figen Oztürk; Işın Soyuer
Journal:  Mol Imaging Radionucl Ther       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.